Ocugen's Amsterdam Office Opens While a 250 Million Share Question Stalls at the Ballot Box

Ocugen names Jolanda Crombach to lead a new Amsterdam subsidiary, but its plan to add 250 million authorized shares failed to reach a vote.

Ocugen is trying to buy itself some goodwill with a fresh face in Europe. Jolanda Crombach will head the company's newly created Amsterdam subsidiary, a post designed to build regulatory capacity on the continent and lay the groundwork for eventual commercialization.

Investors greeted the appointment warmly, lifting the shares 2.5% to EUR 0.9550. Whether a European beachhead can quiet the far louder noise coming from the company's own shareholder base is another matter entirely.

The rationale behind Crombach's hire is straightforward. A global biotech asset is hard to establish without meaningful European market access, and pursuing approvals there demands both local experience and patience. Building out a new overseas structure, however, consumes real resources — the kind Ocugen cannot currently take for granted.

A Proxy Fight That Never Got Off the Ground

That tension sits at the center of Ocugen's current predicament. Management wants to expand the number of authorized common shares by 250,000,000 to create financial breathing room. The proposal failed to muster enough support to even formally open voting, and previously submitted proxies remain valid unless revoked.

This is the second time the measure has been shelved. Roughly two weeks earlier, an initial attempt collapsed after only 47.3% of outstanding common shares showed up — short of quorum. The stock has since added 1.3%, but the message from the ownership base is hard to miss: retail investors are tired of watching development-stage companies issue fresh paper to fund expensive trial programs.

The math is unforgiving. New capital keeps a research-driven biotech alive during years without recurring product revenue, yet every additional share dilutes existing holders' claim on future success. The resistance lays bare how thin the ice has become for cash-burning biotechs in the current environment.

Conference Stages Full, Coffers Empty

The contrast with Ocugen's public posture is striking. On international industry panels, management happily positions itself as a driving force behind novel therapies for blindness. Scientific ambition, though, does not pay salaries, lab equipment, or clinical trial costs.

The company has hardly been idle on the science front. It recently presented research data on the OCU410 and OCU410ST programs at the Euretina congress. Presentations on its modifier gene therapy platform are also scheduled for the American Academy of Ophthalmology annual meeting on October 9 and 11, 2026, where the therapy is to be made available through an expanded access program to treat the first retinitis pigmentosa patients.

On September 30, Ocugen announced planned presentations on that same platform at upcoming scientific conferences. A day earlier, it disclosed that executives would attend two investor and industry conferences — a visible push to win over institutional accounts and spotlight the pipeline's scientific potential.

Adding some speculative fuel more than a month ago was word of a preliminary approval in the Bahamas. The Longevity and Regenerative Therapies Board granted candidate OCU400 priority status under an expanded access program for retinitis pigmentosa, albeit contingent on full approval.

The Gap Between Hope and the Tape

None of these incremental wins has broken the broader downtrend. The stock trades 59% below its 52-week high, and in today's session it sits at EUR 0.9210, down 1.2% on the day. Over twelve months, the losses now total 41%.

The repeated postponement gives the board a breather but does nothing to remove the blockage. Until Ocugen squares its research ambitions with a durable capital base, the Amsterdam expansion remains a bet placed on credit it has not yet secured.